Company Overview and News

 
Can NAB's Mike Baird help bankers deal with their reputation woes?

2018-09-21 theage.com.au
When Mike Baird announced his shock resignation as NSW premier, it didn't take long for his phone to start ringing with job offers. Within two days, National Australia Bank chief Andrew Thorburn was one of those callers, getting in touch with Baird, who was already a friend through their church.
PRY NAUBF DB NAB NASXF PHCRF NABZY SIV PHCRY

 
Can NAB's Mike Baird help bankers deal with their reputation woes?

2018-09-21 smh.com.au
When Mike Baird announced his shock resignation as NSW premier, it didn't take long for his phone to start ringing with job offers. Within two days, National Australia Bank chief Andrew Thorburn was one of those callers, getting in touch with Baird, who was already a friend through their church.
PRY NAUBF DB NAB NASXF PHCRF NABZY SIV PHCRY

 
ASX rallies despite trade tariff concerns

2018-09-17 theage.com.au
Australian shares rallied from a 20 point fall at the open to close the session higher despite lingering uncertainty over the future of US trade tariffs against China.
PRY PLS PILBF PHCRF JRHHY EHE JHC PHCRY REG

 
ASX rallies despite trade tariff concerns

2018-09-17 smh.com.au
Australian shares rallied from a 20 point fall at the open to close the session higher despite lingering uncertainty over the future of US trade tariffs against China.
PRY PLS PILBF PHCRF JRHHY EHE JHC PHCRY REG

 
Dorevitch workers get up to 20pc pay rise, Primary profit to take a hit

2018-09-14 theage.com.au
Primary Health Care will have to grant pay rises of up to 20 per cent to more than 600 workers in its Victorian pathology division after a Fair Work Commission ruling that also awarded workers higher allowances and backpay.
PRY PHCRF PHCRY

 
Dorevitch workers get up to 20pc pay rise, Primary profit to take a hit

2018-09-14 smh.com.au
Primary Health Care will have to grant pay rises of up to 20 per cent to more than 600 workers in its Victorian pathology division after a Fair Work Commission ruling that also awarded workers higher allowances and backpay.
PRY PHCRF PHCRY

2
Markets Live: ASX closes at lowest value since June

2018-09-10 theage.com.au
Below is William's market wrap. I will be back editing tomorrow. CSL is going ex-dividend tomorrow by 127.8 cents, and NAB's business conditions indicator will be out in the morning.
BGCHY RIO BLT RIO MAYNF OGFGY OISHF BEPTF RTPPF MYX RTNTF INCZY OSH PRY OISHY BHPBF BGA WTCHF BCHEY MYPHY PHCRY BPT PTM BHP RIO BBL PHCRF BHP OGFGF BHPLF ICPVF IPL ORG

2
ASX notches up eight straight losses

2018-09-10 theage.com.au
Australian shares have fallen for an eighth straight session, its longest losing streak since the global financial crisis.
RIO BLT RIO NST MAYNF SKHCY LGTHY CIM RTPPF RTNTF PRY SHL SKHHY BHPBF WTCHF PHCRY NESRF SKHCF BHP RIO BBL PHCRF BHP NHRNY LGTHF BHPLF

2
ASX notches up eight straight losses

2018-09-10 smh.com.au
Australian shares have fallen for an eighth straight session, its longest losing streak since the global financial crisis.
RIO BLT RIO NST MAYNF SKHCY LGTHY CIM RTPPF RTNTF PRY SHL SKHHY BHPBF WTCHF PHCRY NESRF SKHCF BHP RIO BBL PHCRF BHP NHRNY LGTHF BHPLF

2
Markets Live: ASX closes at lowest value since June

2018-09-10 smh.com.au
Below is William's market wrap. I will be back editing tomorrow. CSL is going ex-dividend tomorrow by 127.8 cents, and NAB's business conditions indicator will be out in the morning.
BGCHY RIO BLT RIO MAYNF OGFGY OISHF BEPTF RTPPF MYX RTNTF INCZY OSH PRY OISHY BHPBF BGA WTCHF BCHEY MYPHY PHCRY BPT PTM BHP RIO BBL PHCRF BHP OGFGF BHPLF ICPVF IPL ORG

 
Primary Health Care Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-20 seekingalpha
The following slide deck was published by Primary Health Care Ltd. ADR in conjunction with their 2018 Q4 earnings call.
PRY PHCRF PHCRY

 
Primary Health Care reveals $250m equity raising, ups profit, revenue

2018-08-20 theage.com.au
Primary Healthcare has launched a $250 million equity raising, underwritten by Morgan Stanley and UBS, to fund its medical centre and pathology investments and a potential acquisition.
PRY PHCRF MS PHCRY

 
Primary Health Care reveals $250m equity raising, ups profit, revenue

2018-08-20 smh.com.au
Primary Healthcare has launched a $250 million equity raising, underwritten by Morgan Stanley and UBS, to fund its medical centre and pathology investments and a potential acquisition.
PRY PHCRF MS PHCRY

 
Primary Health Care shares drop more than 5pc on lower profit outlook

2018-08-13 theage.com.au
Primary Health Care's shares tumbled more than 5 per cent on Monday, with the company revealing it expected underlying profit after tax to be at the lower end of guidance range of $92 million to $97 million.
PRY PHCRF PHCRY

 
Primary Health Care shares drop more than 5pc on lower profit outlook

2018-08-13 smh.com.au
Primary Health Care's shares tumbled more than 5 per cent on Monday, with the company revealing it expected underlying profit after tax to be at the lower end of guidance range of $92 million to $97 million.
PRY PHCRF PHCRY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:PRY / PRIMARY HEALTH CARE LIMITED on message board site Silicon Investor.

PRYD - Digital Mafia PRYD - Digital Mafia PRYD - Digital Mafia Esprit Telecom Group plc ADR - ESPRY Esprit Telecom Group plc ADR - ESPRY Esprit Telecom Group plc ADR - ESPRY